BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 268.74M | 348.90M | 520.42M | 657.24M | 523.88M |
| Total Depreciation and Amortization | 66.50M | 72.16M | 82.73M | 83.25M | 91.15M |
| Total Amortization of Deferred Charges | 7.40M | 7.40M | -- | -- | -- |
| Total Other Non-Cash Items | 695.74M | 693.20M | 523.59M | 318.91M | 286.71M |
| Change in Net Operating Assets | -164.13M | -293.66M | -212.76M | -292.62M | -201.47M |
| Cash from Operations | 874.25M | 827.99M | 913.98M | 766.77M | 700.26M |
| Capital Expenditure | -107.19M | -103.04M | -81.85M | -71.86M | -76.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -285.19M | -285.19M | -285.19M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 731.91M | -26.01M | 71.65M | 91.28M | 198.58M |
| Cash from Investing | 339.52M | -414.24M | -295.39M | 19.42M | 122.49M |
| Total Debt Issued | 850.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -494.99M | -494.99M |
| Issuance of Common Stock | 14.46M | 14.46M | 15.58M | 20.37M | 42.08M |
| Repurchase of Common Stock | -45.37M | -55.97M | -58.17M | -61.91M | -66.39M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.54M | -889.00K | -94.00K | -3.12M | -3.14M |
| Cash from Financing | 809.55M | -42.39M | -42.69M | -539.65M | -522.43M |
| Foreign Exchange rate Adjustments | 305.00K | -2.52M | -1.24M | -4.88M | 1.49M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.02B | 368.84M | 574.66M | 241.67M | 301.81M |